Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
T-Cell Protect Hellas is a Greece-based nutraceutical and consumer health company marketing immune support dietary supplements under the TCELL Protect brand. The company positions its flagship product as an over-the-counter, clinical-grade 3CL protease inhibitor supplement composed of plant extracts and other proprietary ingredients intended to support immune function and reduce viral replication. Its business appears focused on commercialization and distribution rather than traditional drug development, and public materials emphasize direct-to-consumer sales and global distribution. T-Cell Protect has also previously entered licensing and distribution arrangements related to Todos Medical's Tollovid products in Europe and Greece. Overall, the company is best characterized as a commercial-stage nutraceutical business operating adjacent to infectious disease and immune health rather than as a clinical-stage biotech developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on T-Cell Protect Hellas.